Great strides have been made in the diagnosis and treatment of cancer. However, a variety of challenges remain that frustrate both physicians and patients. Central to this is how to use the large amounts of genetic data now available. Dr Chris Gaj explores the challenges and potential consequences for stakeholders in the US, Europe and emerging markets.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,